Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0S3EM
|
||||
Former ID |
DNCL003358
|
||||
Drug Name |
CAZ AVI
|
||||
Synonyms |
CAZ104
|
||||
Indication | Serious infections [ICD9: 001-139; ICD10:A00-B99] | Phase 3 | [1] | ||
Company |
AstraZeneca
|
||||
Target and Pathway | |||||
Target(s) | Beta-lactamase | Target Info | Modulator | [2] | |
References | |||||
REF 1 | ClinicalTrials.gov (NCT01644643) Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens. U.S. National Institutes of Health. | ||||
REF 2 | NXL104 irreversibly inhibits the beta-lactamase from Mycobacterium tuberculosis. Biochemistry. 2012 Jun 5;51(22):4551-7. Epub 2012 May 22. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.